A preliminary pharmacogenetic investigation of adverse events from topiramate in heavy drinkers.

Topiramate, an anticonvulsant medication, is an efficacious treatment for alcohol dependence. To date, little is known about genetic moderators of side effects from topiramate. The objective of this study was to examine 3 single nucleotide polymorphisms (SNPs) of the glutamate receptor GluR5 gene (GRIK1) as predictors of topiramate-induced side effects in the context of a laboratory study of topiramate. Heavy drinkers (n=51, 19 women and 32 men), 75% of whom met criteria for an alcohol use disorder, completed a 5-week dose escalation schedule to a target dose of either 200 or 300 mg or matched placebo. The combined medication groups were compared with placebo-treated individuals for side effects at target dose. Analyses revealed that an SNP in intron 9 of the GRIK1 gene (rs2832407) was associated with the severity of topiramate-induced side effects and with serum levels of topiramate. Genes underlying glutamatergic neurotransmission, such as the GRIK1 gene, may help predict heterogeneity in topiramate-induced side effects. Future studies in larger samples are needed to more fully establish these preliminary findings.

[1]  D. Ciraulo,et al.  Safety and efficacy of GABAergic medications for treating alcoholism. , 2005, Alcoholism, clinical and experimental research.

[2]  R Plomin,et al.  DNA by Mail: An Inexpensive and Noninvasive Method for Collecting DNA Samples from Widely Dispersed Populations , 1997, Behavior genetics.

[3]  D. Goldman,et al.  Genomics and Variation of Ionotropic Glutamate Receptors , 2003, Annals of the New York Academy of Sciences.

[4]  L. Ray,et al.  Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study. , 2007, Archives of general psychiatry.

[5]  R. Williamson,et al.  SIMPLE NON-INVASIVE METHOD TO OBTAIN DNA FOR GENE ANALYSIS , 1988, The Lancet.

[6]  M. Rogawski,et al.  Topiramate selectively protects against seizures induced by ATPA, a GluR5 kainate receptor agonist , 2004, Neuropharmacology.

[7]  Sanjay M Sisodiya,et al.  Potential genetic causes of heterogeneity of treatment effects. , 2007, The American journal of medicine.

[8]  Mark Daly,et al.  Haploview: analysis and visualization of LD and haplotype maps , 2005, Bioinform..

[9]  P. Dodd,et al.  Glutamate-mediated transmission, alcohol, and alcoholism , 2000, Neurochemistry International.

[10]  F. Weiss,et al.  Behavioral Neurobiology of Alcohol Addiction: Recent Advances and Challenges , 2002, The Journal of Neuroscience.

[11]  R. Serlin,et al.  Misuse of statistical test in three decades of psychotherapy research. , 1994, Journal of consulting and clinical psychology.

[12]  M. Rogawski,et al.  Selective Antagonism of GluR5 Kainate-Receptor-Mediated Synaptic Currents by Topiramate in Rat Basolateral Amygdala Neurons , 2003, The Journal of Neuroscience.

[13]  C. E. Elger,et al.  Efficacy and cognitive side effects of tiagabine and topiramate in patients with epilepsy , 2005, Epilepsy & Behavior.

[14]  N. Ait-Daoud,et al.  Neuropharmacological treatments for alcoholism: scientific basis and clinical findings , 2000, Psychopharmacology.

[15]  D. Ciraulo,et al.  Topiramate for treating alcohol dependence: a randomized controlled trial. , 2007, JAMA.

[16]  D. Rohsenow,et al.  Using acquired knowledge and new technologies in alcoholism treatment trials. , 2002, Alcoholism, clinical and experimental research.

[17]  D. Couper,et al.  An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. , 2008, Archives of general psychiatry.

[18]  E. Spitz,et al.  Comparative diagnoses of twin zygosity by SSLP variant analysis, questionnaire, and dermatoglyphic analysis , 1996, Behavior genetics.

[19]  D. Oslin,et al.  A Functional Polymorphism of the μ-Opioid Receptor Gene is Associated with Naltrexone Response in Alcohol-Dependent Patients , 2003, Neuropsychopharmacology.

[20]  A. Barbon,et al.  Genomic organization, proposed alternative splicing mechanisms, and RNA editing structure of GRIK1 , 2000, Cytogenetic and Genome Research.

[21]  Jennie Z Ma,et al.  Oral topiramate for treatment of alcohol dependence: a randomised controlled trial , 2003, The Lancet.

[22]  Josemir W Sander,et al.  Effects of topiramate on cognitive function , 2000, Journal of neurology, neurosurgery, and psychiatry.

[23]  J A Tischfield,et al.  Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[24]  S A Maisto,et al.  Reliability of alcohol abusers' self-reports of drinking behavior. , 1979, Behaviour research and therapy.

[25]  C. O'brien.  Prospects for a genomic approach to the treatment of alcoholism. , 2008, Archives of general psychiatry.

[26]  J. Krystal,et al.  Antiglutamatergic strategies for ethanol detoxification: comparison with placebo and diazepam. , 2007, Alcoholism, clinical and experimental research.

[27]  D. Oslin,et al.  A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. , 2003, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[28]  L. Hai.  Collection of genomic DNA of large samples from mailed mouthwashes , 2009 .

[29]  K. Livak,et al.  Allelic discrimination using fluorogenic probes and the 5' nuclease assay. , 1999, Genetic analysis : biomolecular engineering.

[30]  T. Rebbeck,et al.  Collection of genomic DNA by buccal swabs for polymerase chain reaction-based biomarker assays. , 1999, Environmental health perspectives.

[31]  J. McGeary,et al.  Effects of topiramate on urge to drink and the subjective effects of alcohol: a preliminary laboratory study. , 2008, Alcoholism, clinical and experimental research.

[32]  J. Littleton.  Neurochemical Mechanisms Underlying Alcohol Withdrawal , 1998, Alcohol health and research world.

[33]  S. Hyman,et al.  Addiction and the brain: The neurobiology of compulsion and its persistence , 2001, Nature Reviews Neuroscience.

[34]  F. Bloom,et al.  Oral alcohol self-administration stimulates dopamine release in the rat nucleus accumbens: genetic and motivational determinants. , 1993, The Journal of pharmacology and experimental therapeutics.

[35]  J Licinio,et al.  Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response , 2004, Molecular Psychiatry.

[36]  D. Hamer,et al.  A functional polymorphism in the monoamine oxidase A gene promoter , 1998, Human Genetics.

[37]  J. Manzanares,et al.  Effects of topiramate in the treatment of alcohol dependence. , 2004, Pharmacopsychiatry.

[38]  T Foitzi,et al.  Allelic discrimination using fluorogenic probes and the 5' nuclease assay , 1999 .